{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:32:28Z","timestamp":1778254348762,"version":"3.51.4"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:p>Alopecia areata (AA) is an inflammatory condition characterized by nonscarring alopecia, of which the pathogenesis has been hypothesized to be a multifactorial process involving genetic, environmental and autoimmune aspects. AA shares multiple gene loci and pathomechanisms with other autoimmune disorders, including multiple sclerosis (MS). Drug-induced AA is a concept that is underreported and poorly understood. Current MS-targeted treatments involve reconstitution of the immune system, with cases of AA being reported. However, translational work has shown novel MS treatments to be beneficial in treating AA and they are currently being trialled for this purpose. We outline the literature within this field to increase awareness and inform patients and clinicians.<\/jats:p>","DOI":"10.1093\/ced\/llaf222","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:45:51Z","timestamp":1747669551000},"page":"2044-2045","source":"Crossref","is-referenced-by-count":2,"title":["Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4874-0874","authenticated-orcid":false,"given":"Hannah","family":"Ross","sequence":"first","affiliation":[{"name":"Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0563-8690","authenticated-orcid":false,"given":"Matthew J","family":"Harries","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]},{"name":"Centre for Dermatology Research, Faculty of Biology, Medicine and Health, University of Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5927-6998","authenticated-orcid":false,"given":"Marta","family":"Bertolini","sequence":"additional","affiliation":[{"name":"Monasterium Laboratory GmbH, a QIMA Life Sciences company , Muenster ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-8377","authenticated-orcid":false,"given":"Leila","family":"Asfour","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2025092509013876900_llaf222-B1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini","year":"2020","journal-title":"Exp Dermatol"},{"key":"2025092509013876900_llaf222-B2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1600-0625.2011.01427.x","article-title":"Alopecia areata as a model for T cell-dependent autoimmune diseases","volume":"21","author":"Bertolini","year":"2012","journal-title":"Exp Dermatol"},{"key":"2025092509013876900_llaf222-B3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025092509013876900_llaf222-B4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/cells9061396","article-title":"The meaning of immune reconstitution after alemtuzumab therapy in multiple sclerosis","volume":"9","author":"Rolla","year":"2020","journal-title":"Cells"},{"key":"2025092509013876900_llaf222-B5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cei\/uxac088","article-title":"Stratification of alopecia areata reveals involvement of CD4\u2005T cell populations and altered faecal microbiota","volume":"210","author":"Bain","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2025092509013876900_llaf222-B6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/CPJ.0000000000001126","article-title":"Skin autoimmunity secondary to alemtuzumab in a tertiary care Spanish hospital","volume":"12","author":"L\u00f3pez Ruiz","year":"2022","journal-title":"Neurol Clin Pract"},{"key":"2025092509013876900_llaf222-B7","doi-asserted-by":"crossref","first-page":"17562864221127476","DOI":"10.1177\/17562864221127476","article-title":"Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis","volume":"15","author":"Tzanetakos","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"2025092509013876900_llaf222-B8","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.3390\/ijerph18147338","article-title":"Alopecia universalis occurring after alemtuzumab treatment for multiple sclerosis. a two-year follow-up of two patients","volume":"18","author":"Borriello","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2025092509013876900_llaf222-B9","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1212\/NXI.0000000000000516","article-title":"Case of alemtuzumab-related alopecia areata management in MS","volume":"6","author":"Chan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025092509013876900_llaf222-B10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.msard.2018.12.005","article-title":"Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: a secondary autoimmune disease","volume":"27","author":"Alcal\u00e1","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025092509013876900_llaf222-B11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2017.00569","article-title":"Alopecia universalis following alemtuzumab treatment in multiple sclerosis: a barely recognized manifestation of secondary autoimmunity \u2013 case report and review of literature","volume":"8","author":"Zimmermann","year":"2017","journal-title":"Front Neurol"},{"key":"2025092509013876900_llaf222-B12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaad.2023.05.022","article-title":"Drug-induced alopecia areata: a systematic review","volume":"90","author":"Ezemma","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"11 Suppl","key":"2025092509013876900_llaf222-B13","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/j.jid.2023.09.098","article-title":"Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse","volume":"143","author":"Rouill\u00e9","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"10 Suppl","key":"2025092509013876900_llaf222-B14","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/j.jid.2021.08.021","article-title":"Sphingosine 1-phosphate receptor signalling promotes hair growth and inhibits perifollicular T-cell expansion and immune privilege collapse ex vivo","volume":"141","author":"Piccini","year":"2021","journal-title":"J Invest Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf222\/63237576\/llaf222.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/2044\/63237576\/llaf222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/2044\/63237576\/llaf222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:01:44Z","timestamp":1758805304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/10\/2044\/8137957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5,19]]},"published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf222","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,19]]}}}